Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Bionomics Ltd ADR

Company price
None USD 0.00(0%)
Last update at 2025-03-23T19:03:56.745549Z
Market Cap
10.43M

Momentum Score

…

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.84
Low
5.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.01
Dividend Yield
-
Revenue TTM
0.66M
Revenue Per Share
0.07
Gross Profit TTM
-18.96M
Debt / Equity
0.02
ROE
-80.80%
Net Debt
-17.72M
ROCE
-81.04%
Diluted EPS TTM
-1.96

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -32.05M -21.95M -8.88M -6.03M -9.91M
Net income -31.85M -21.76M -8.70M -5.82M -9.67M
Selling general administrative 8.86M 11.40M 5.65M 5.47M 9.35M
Gross profit 0.02M 0.00M - 0.05M 3.82M
Reconciled depreciation 1.16M 1.11M 1.70M 2.17M 1.71M
Ebit -31.50M -21.34M -10.20M -6.52M -9.25M
Ebitda -30.35M -20.23M -8.50M -4.35M -7.54M
Depreciation and amortization 1.16M 1.11M 1.70M 2.17M 1.71M
Operating income -31.50M -21.34M -10.20M -6.52M -9.25M
Other operating expenses 27.84M 21.61M 13.02M 12.74M 19.18M
Interest expense 0.02M 0.03M 1.44M 1.85M 2.36M
Tax provision -0.21M -0.19M -0.19M -0.21M -0.24M
Interest income 0.48M 0.01M 0.01M 0.06M 0.28M
Net interest income 0.45M -0.03M -1.44M -1.79M -2.08M
Income tax expense -0.21M -0.19M -0.19M -0.21M -0.24M
Total revenue 0.02M 0.26M - 0.05M 3.82M
Total operating expenses 27.84M 21.61M 13.02M 12.74M 19.18M
Cost of revenue - 0.26M - - -
Total other income expense net -4.68M -0.61M 1.32M 0.50M -0.66M
Discontinued operations - - - -1.30M 0.04M
Net income from continuing ops -31.85M -21.76M -8.70M -5.82M -9.67M
Net income applicable to common shares -31.85M -21.76M -8.70M -7.12M -10.36M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 43.00M 65.31M 54.26M 34.46M 53.66M
Intangible assets 9.20M 9.84M 9.95M 11.77M 12.87M
Other current assets - 1.46M 0.93M 2.92M 7.84M
Total liab 9.86M 8.40M 6.67M 21.78M 35.96M
Total stockholder equity 33.15M 56.91M 47.60M 12.68M 17.70M
Other current liab 1.89M 3.44M 1.16M 1.06M 3.92M
Common stock 223.41M 217.70M 190.19M 148.16M 144.94M
Capital stock 223.41M 217.70M 190.19M 148.16M 144.94M
Retained earnings -204.77M -173.31M -154.04M -148.89M -140.87M
Other liab 5.36M 4.51M 3.61M 7.22M 13.51M
Good will 13.08M 12.87M 12.40M 12.87M 12.76M
Other assets 0.12M 0.12M 0.12M 0.44M 0.38M
Cash 18.25M 33.56M 28.50M 4.58M 13.99M
Total current liabilities 4.13M 3.36M 2.36M 8.27M 13.80M
Current deferred revenue - -1.80M - - 0.23M
Net debt -17.72M -32.87M -27.63M 7.66M 3.11M
Short term debt 0.17M 0.16M 0.17M 5.95M 8.45M
Short long term debt - - - 5.19M 8.45M
Short long term debt total 0.53M 0.69M 0.87M 12.24M 17.10M
Other stockholder equity 14.51M 12.52M 11.45M 13.41M 13.62M
Property plant equipment 0.50M 0.67M 0.87M 1.05M 2.51M
Total current assets 20.10M 41.81M 30.93M 8.33M 25.13M
Long term investments - - 0.12M 0.44M 0.38M
Net tangible assets 10.86M 34.21M 25.25M -11.96M -9.14M
Short term investments - - 0.44M - 0.55M
Net receivables 0.64M 6.78M 0.20M 0.06M 0.89M
Long term debt - - - 6.26M 8.65M
Inventory - - 0.86M 0.77M 0.66M
Accounts payable 2.06M 1.56M 1.03M 1.26M 1.20M
Accumulated other comprehensive income 14.51M 12.52M 11.45M 13.41M 13.62M
Non currrent assets other 0.12M 0.12M - - -
Non current assets total 22.91M 23.50M 23.34M 26.13M 28.53M
Capital lease obligations 0.53M 0.69M 0.87M 0.79M -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.19M 0.61M -0.12M 0.50M 0.50M
Change to liabilities 0.51M 0.79M -0.25M -0.12M -1.65M
Total cashflows from investing activities 0.48M 0.62M -0.08M -0.20M 0.20M
Net borrowings -0.16M -0.17M -11.87M -8.29M -5.33M
Total cash from financing activities 5.60M 27.00M 31.55M -5.36M 4.35M
Change to operating activities 6.41M -6.35M 1.85M 4.39M -0.18M
Net income -31.85M -21.76M -8.70M -5.82M -9.67M
Change in cash -15.31M 5.07M 23.92M -9.41M -10.94M
Begin period cash flow 33.56M 28.50M 4.58M 13.99M 24.93M
End period cash flow 18.25M 33.56M 28.50M 4.58M 13.99M
Total cash from operating activities -21.10M -21.76M -7.54M -3.90M -15.58M
Issuance of capital stock 7.42M 32.89M 32.94M 2.24M 7.07M
Depreciation 1.16M 1.11M 1.70M 2.17M 1.71M
Other cashflows from investing activities 0.48M 0.01M 0.00M -0.95M 0.28M
Dividends paid - - 0.36M 0.78M 0.42M
Change to inventory - 0.00M - -0.03M -0.15M
Change to account receivables 0.05M -0.04M 0.03M -0.20M -0.15M
Sale purchase of stock - 0.00M -0.42M -0.05M -0.42M
Other cashflows from financing activities -1.66M -5.72M -0.42M -0.33M 0.42M
Change to netincome 2.38M 4.50M -2.43M -3.02M -4.52M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.10M
Change in working capital 6.97M -5.60M - - -
Stock based compensation 1.90M 2.83M - - -
Other non cash items 0.51M 1.67M 8.70M 7.12M 9.67M
Free cash flow -21.10M -21.76M -7.54M -3.91M -15.68M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Bionomics Ltd ADR

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

200 Greenhill Road, Eastwood, SA, Australia, 5063

61 8 8150 7400

Name Title Year Born
Dr. Errol B. De Souza Ph.D. Exec. Chairman 1953
Mr. Adrian Hinton BEC, F.C.A. Acting Chief Financial Officer 1952
Mr. Connor Bernstein M.Sc. VP of Strategy & Corp. Devel. 1988
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Consultant Chief Medical Officer of Clinical Neuroscience NA
Ms. Suzanne Irwin B.Com., FCIS Company Sec. NA
Ms. Suzanne Irwin B.Com., FCIS Company Secretary NA
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 1973
Mr. Adrian Hinton BEC, F.C.A. Financial Controller 1953
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer 1963
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…